Cadila forays into US generics market

Comments 0
Cadila Pharmaceuticals has launched the world’s first innovative drug treatment for lung cancer — Mycidac-C. Cadila Pharmaceuticals has launched the world’s first innovative drug treatment for lung cancer — Mycidac-C.
SummaryLaunches lung cancer drug at Rs 40k in India; same drug sells for over Rs 2 lakh globally.

US generic foray, Modi said that all the filings have been made from the company’s Dholka plant in Gujarat, which is USFDA approved.

India accounts for about 40% of generic and over-the-counter products and 10% of finished dosages used in the US.

Cadila sells products in over 50 countries and caters to over 45 therapeutic areas including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, anti-diabetics and immunologicals.

Single Page Format
Ads by Google

More from Corporates & Markets

Reader´s Comments
| Post a Comment
Please Wait while comments are loading...